TrialJAMA oncology2016

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Mark A Dickson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.